|
WO2021046407A1
|
|
Rip1 inhibitory compounds and methods for making and using the same
|
|
WO2021046437A1
|
|
Rip1 inhibitory compounds and methods for making and using the same
|
|
US2021061798A1
|
|
Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
|
|
WO2021030526A1
|
|
Method of blocking or ameliorating cytokine release syndrome
|
|
WO2021026451A1
|
|
Compounds and method for treating cytokine release syndrome
|
|
WO2020243612A1
|
|
Method of preventing and treating thrombosis
|
|
CA3101983A1
|
|
Quinoline derivatives useful as tyrosine kinase inhibitors
|
|
CN112004808A
|
|
Prodrugs of NRF 2-activating compounds and uses thereof
|
|
WO2019213447A1
|
|
Rip1 inhibitory compounds and methods for making and using the same
|
|
AU2019262142A1
|
|
RIP1 inhibitory compounds and methods for making and using the same
|
|
EP3645525A1
|
|
Kinase inhibitors and methods for making and using
|
|
US2019382496A1
|
|
Acvr2a-specific antibody and method of use thereof
|
|
US2018155422A1
|
|
Antigen binding molecules to TIGIT
|
|
CN110234637A
|
|
Pyrazole amide compound as IRAK inhibitor
|
|
EP3532470A1
|
|
Oxazole derivatives for use as irak inhibitors and method for their preparation
|
|
EP3500558A1
|
|
Benzimidazole direct ampk activators
|
|
WO2018009938A1
|
|
Tyrosine kinase inhibitors
|
|
CA3028997A1
|
|
2,4-diamino-pyrimidine compounds and method for making and using the compounds
|
|
US2017217922A1
|
|
Nrf2 activating compounds and uses thereof
|
|
CN108699034A
|
|
NRF2 reactivity compounds and application thereof
|
